Read more

An influential Iron-Deficiency Anemia Therapy market report covers an array of factors that have an influence on the market and healthcare industry which includes industry insight and critical success factors (CSFs), market segmentation and value chain analysis, industry dynamics, drivers, Read more

Top Players Covered in the Hyperphosphatemia Treatment Market Research Report are Sanofi (Paris, France), Takeda Pharmaceutical Company Limited (Tokyo, Japan), Astellas Pharma Inc. (Tokyo, Japan), Akebia Therapeutics, Inc (Massachusetts, U.S.), Vifor Pharma Management Ltd. (Zurich, Switzerland), Lupin Limited (Mumbai, India), Ardelyx, Inc. (California, U.S.), Unicycive Therapeutics Inc. (California, U.S), Keryx Biopharmaceuticals (Massachusetts, U.S.), Zeria Pharmaceutical (Chuo City, Japan), Other Prominent Players Top Players Covered in the Hyperphosphatemia Treatment Market Research Report are Sanofi (Paris, France), Takeda Pharmaceutical Company Limited (Tokyo, Japan), Astellas Pharma Inc. (Tokyo, Japan), Akebia Therapeutics, Inc (Massachusetts, U.S.), Vifor Pharma Management Ltd. (Zurich, Switzerland), Lupin Limited (Mumbai, India), Ardelyx, Inc. (California, U.S.), Unicycive Therapeutics Inc. (California, U.S), Keryx Biopharmaceuticals (Massachusetts, U.S.), Zeria Pharmaceutical (Chuo City, Japan), Other Prominent Players Read more

Read more

CAMBRIDGE, Mass., Aug. 5, 2021 /PRNewswire/ -- Akebia Therapeutics Read more

The company, Akebia Therapeutics Inc, is set to host investors and clients on a conference call on 8/5/2021 9:39:55 PM. The call comes after the company''s earnings, which are set to be announced on 8/5/2021.Investors, or members of the public who wish to dial in, can join the call by visiting Read more

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Akebia Therapeutics, Inc. (Akebia or the Company) (NASDAQ: AKBA) who formerly held shares of Keryx Biopharmaceuticals, Inc. (KERX) for violations of the securities laws. If you are a shareholder, click here to participate. We also encourage you Read more

SAN DIEGO--(BUSINESS WIRE)---- $akba #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQ:AKBA) common stock in the December 2018 transaction by which Keryx became a wholly owned subsidiary of Akebia. Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology. At the Read more

Akebia Therapeutics, Inc. (NASDAQ:AKBA) with the stream of 2.25% also noticed, India Morgan Stanley (NYSE:MS) encountered a rapid change of 3.85% in the last hour of Wednesdays trading session. Akebia The post Hot Stock That Must Be in Your Portfolio: Akebia Therapeutics, Inc. (NASDAQ:AKBA), Morgan Stanley (NYSE:MS) appeared first on Stocks Equity . Read more

NEW YORK , July 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA. Read more

CAMBRIDGE, Mass., July 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 25 newly-hired employees options to purchase an aggregate of 210,000 shares of Akebia''s Read more

During Q1, Akebia Therapeutics (NASDAQ: AKBA ) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. In Q4, Akebia Therapeutics brought in $56.70 million in sales but lost $85.40 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of Full story available on Benzinga.com Read more

During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 Read more

Read more

Read more